BEIJING (Reuters) – China’s market regulator said on Monday it had tightened up a guideline for inspection of biological products, including vaccines, before a batch is sold or imported.
The new guideline, effective from March 1 next year, adds a requirement that provincial-level medical product regulators are responsible for investigating major flaws that could impact product quality in companies’ manufacturing process in their region, State Administration For Market Regulation said on its website.
The new guideline also specifies situations where inspection of pre-sale or pre-imported batches of such products could be waived, SAMR said.
China has allowed vaccines, if they are used to cope with infectious disease epidemics or other emergencies, to be exempted from inspection procedures, known as lot release, after approval from State Council’s medical product regulating department.
Source: Read Full Article
'You'll have children that will never be able to go on a bouncy castle again' – Government urged to tackle insurance costs
‘The blue wall is crumbling,’ policing will fundamentally change after Chauvin verdict, says former NAACP CEO
Global stock markets surge after Pfizer Covid vaccine news
Dow, S&P close at records as Disney offsets drop in sentiment
U.S. expected to unveil emergency oil release in bid to fight high prices